Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hope life's good at The Seattle Yacht Club sir.
Thanks for sharing.
Endorphin time.
IO Biotech is also collaborating with key scientists at University of Copenhagen, Herlev Hospital, The Lankenau Institute for Medical Research, Georgetown University and Verona University.
Collaboration with Merck began Feb 28, 2018.
They also attended The Jamie Dimon partnering event in January 2021.
https://www.iobiotech.com/index.php/partnering
I wish IO Biotech success and hope they have the formula to put a halt to cancer and help mankind.
Enjoy your day AshokaXC.
Immuno-oncology biotech IO Biotech files for a $100M IPO
*plans to enroll for a Phase 3 trial in combination with pembrolizumab.
IO Biotech filed confidentially on June 3, 2021.
Nasdaq symbol is IOBT.
https://awesomecapital.blogspot.com/2021/10/immuno-oncology-biotech-io-biotech.html
Let's see how the road show goes.
MYMX is IOBT's exploratory partner for any new reader's.
Merck also involved.
Staehelin brought Bristol Myers to Biopole.
February 2021.
Lenz & Staehelin acts as Swiss legal advisor to WuXi STA
WuXi STA, a subsidiary of WuXi AppTec, a pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry with global operations, whose shares are listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, entered into an agreement with Bristol Myers Squibb, a company whose shares are listed on the New York Stock Exchange, to purchase Bristol Myers Squibb’s state-of-the-art manufacturing facility with commercial-scale production capacity for capsule and tablet dosage forms located in Couvet, Switzerland.
The companies anticipate completing the transaction by Q2 2021, subject to regulatory approvals and the satisfaction of other closing conditions. Upon closing, WuXi STA will acquire the Couvet site’s operations and assets, which include the plant and equipment, as well as a workforce with technical capabilities and expertise.
The team
Lenz & Staehelin acts as Swiss legal advisor to WuXi STA in this transaction. The team is led by partner Andreas Rötheli (co-head Corporate and M&A – pictured) and includes associates Ralph Kaufmann and Roman Graf (Corporate M&A), Cécile Vulliemin (Real Estate), Sevan Antreasyan (IP, Regulatory & Life Sciences), Sandrine Kreiner, Prisca Cattaneo and Bertrand Donzé (all Employment), and Benoît Biedermann (Tax). DLA Piper Hong Kong and New York acts as lead counsel to WuXi STA in this transaction.
https://legalcommunity.ch/wuxi-sta-acquires-manufacturing-facility-couvet-bristol-myers-squibb/
https://www.stapharma.com/en/news/newsroom/wuxi-sta-completes-acquisition-of-bristol-myers-squibb-manufacturing-facility-in-couvet-switzerland/
IO Biotech, Inc. (IOBT)
IO Biotech will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
**in combination with nivolumab**
https://stockanalysis.com/stocks/iobt/company/
Speaking of catalyst...
BIOPÔLE | A CATALYSER FOR LIFE SCIENCES INNOVATORS
Join the BioAlps community for the 4à6 @ Biopôle from 4:30PM to 7PM on Tuesday 19 October 2021.
https://www.biopole.ch/event/4a6-biopole/
Maybe Hugo and Carmelina can attend.
Big tobacco isn't the only one.
California, U.S. and Incheon, S. Korea, October 7, 2021.
Enzolytics Inc.
https://enzolytics.com/company-news/
Hugo and The Basel King are still on deck with those two catalyst for the 2nd half of 2021.
They have to let those books dry out from all of Fruci's cleaning.
Hope life is good WH.
Dr. Volker Thiel and Rockefeller University.
https://twitter.com/ProfVolkerThiel
October 14, 2021.
https://www.rockefeller.edu/news/31414-noninfectious-sars-cov-2-replicons-provide-powerful-research-tools/
https://www.science.org/doi/10.1126/science.abj8430
Ulrich Burkhard, MFO's Investment Outlook (October 2021)
https://www.marcuardfamilyoffice.com/news/investment-outlook-october-2021/
Dr. Richard Johnson is hiring.
https://www.upperton.com/careers/
Many thanks Amer Jaber.
https://www.businesswire.com/news/home/20211007005511/en/Stallergenes-Greer-Launches-CORAP-Community-for-Research-in-Allergic-Patients-Research-Programme
October 7, 2021.
Free Ernesto Bertarelli.
Is this the reason for delay with allergy deal?
https://www.telegraph.co.uk/women/life/kirsty-bertarelli-does-400m-divorce-look-like/
"The right thing has to be done by the right person" -Thomas Staehelin, May 23, 2001.
http://archiv.onlinereports.ch/2001/StaehelinThomasInterview.htm
Has the right thing been done to Mymetics investors Dr. Staehelin?
2. The OTC listing for a company to merge with to get on the market in the U.S.
Sunstone Life Science Ventures is involved with IO Biotech and Anergis.
Take a look under Updates. Specifically, the 2 week and 5 month posts.
https://www.linkedin.com/company/sunstone-life-science-ventures
Sunstone Life Science Ventures General Partner, Claus Andersson has been on IO Biotech's Board of Director's since December 2016.
https://www.linkedin.com/in/clausandersson?trk=org-employees
Series B- IO Biotech Investors:
https://www.crunchbase.com/funding_round/io-biotech-series-b--f982e3ba
IO Biotech's CSO and CFO are already working from the US.
In June, they hired Alireza Alavi as VP, Clinical Biomarkers located in Rockville, MD and also just hired a scientist to work in Rockville,MD.
https://www.linkedin.com/in/alireza-s-alavi
Sunstone recently sold Arctos to Novartis for an undisclosed sum. This would free up capital for them.
IO Biotech co-founder, Dr.Inge Marie Svane is listed on Immunicum's Scientific Advisory Board.
https://immunicum.se/about/scientific-advisory-board/
Tolly's presenting at SACHS Biotech in Europe Forum (October 7-8, 2021).
In 2021, Tollys participated to the MATWIN oncology innovation program and was awarded 'Best-in-Class Innovation" by the International Board of Matwin
https://www.sachsforum.com/21bef-attendees.html
Mymetics not listed as an attendee.
eTheRNA immunotherapies opens office in Hong Kong and subsidiary in New York.
They have raised $63 million in venture funding.
https://www.prnewswire.com/news-releases/etherna-immunotherapies-appoints-mathieu-lane-as-chief-financial-officer-and-president-of-etherna-inc-located-in-the-usa-301341302.html
https://www.prnewswire.com/news-releases/etherna-immunotherapies-opens-office-in-hong-kong-to-support-and-build-on-its-growing-activities-in-china-and-broader-asia-pacific-301346287.html
The following twelve words is the only update investors received in two and a half years from leadership concerning project:
"The project with eTheRNA immunotherapy did not result in the desired responses."
Fruci & Associates, P.C., a FOREIGN PROFIT CORPORATION, opened three months ago.
https://www.bizapedia.com/id/fruci-and-associates-pc.html
Speaking of Bachmann...
Do you think The Bachmann Trust is aware that their old Anglo Irish Bank friend got released from prison?
https://www.irishtimes.com/news/crime-and-law/former-anglo-irish-bank-chief-david-drumm-released-from-prison-1.4485645
Dr. Martin F. Bachmann appears busy.
https://www.bachmannlab.ch/corona/
https://www.deepvax.ch/team/
https://www.saiba-biotech.com/who-we-are/
I was your first follower AhsokaXC.
Appreciate your post.
The International Vaccine Institute, TCH and BCM partner for vaccine research
Sep 28, 2021
https://www.bcm.edu/news/the-international-vaccine-institute-tch-and-bcm-partner-for-vaccine-research
https://twitter.com/drjeromekim1?lang=en
Staehelin's Swiss Rockets were founded in 2018.
Dr. Alex A. Adjei, Chairman of Oncology Advisory Committee and the other members would certainly be an asset navigating Mymetics and IO Biotech through the oncology field.
Mymetics May 2021 Overview, Immuno Oncology Pipeline also stated "Several Not Disclosed Partners."
Thomas Staehelin, Swiss Rockets Co-Founder
September 15, 2021.
https://swissrockets.com/
I hope life is good Extrinsic55.
Is MYMX virosome delivery system being used or needed in the IO Biotech-Merck collaboration is the big question?
It will be fast tracked by FDA if it meets expectations in Rockville.
Mai-Britt Zocca and others stated it was "groundbreaking", hence the upcoming IPO and move to USA.
Merck could just purchase IO Biotech outright beforehand.
Also, Dr. Maria Bottazzi appeared on Alexander Kettner's (Anergis) linkedin page.
Later.
IO Biotech hiring scientist in Rockville,MD.
https://www.linkedin.com/jobs/view/scientist-at-io-biotech-2722972618
Are we still in "exploratory project" with them?
IO Biotech/2021 Sep 13/Affiliations
Arginase 1-based immune modulatory vaccines induce anti-cancer immunity and synergize with anti-PD-1 checkpoint blockade
https://pubmed.ncbi.nlm.nih.gov/34518197/
Virosome Presents Multimodel Cancer Therapy without Viral Replication
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866828/
Sept. 15, 2021. IO Biotech begins phase III trial with partner MSD
Keytruda.
https://medwatch.com/News/Pharma___Biotech/article13284129.ece
Aug. 3, 2021. Ruprecht, Villinger, Radcliffe
Affiliations
*Radcliffe listed at University of Pennsylvania; not UVA.*
Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges.
https://europepmc.org/article/PMC/PMC8370093
wer weiß?
The Swiss National Science Foundation
National Research Programme “COVID-19 in Society” (NRP 80): This NRP will be launched in autumn 2021. Its mission is to generate knowledge that will help us manage the current as well as future pandemics by analyzing social processes during the pandemic from a social science perspective. NRP 80 thus complements NRP 78 “COVID-19”, which focuses primarily on the biomedical and clinical aspects. The programme has a budget of CHF 14 million and will run for three years.
https://www.glopid-r.org/newsletter-15th-edition/the-swiss-national-science-foundation-snsf/
Database: https://www.snf.ch/en/cXGl5KuPUZxOP5bk/news/news-200518-snapshot-of-swiss-research-on-covid-19
https://data.snf.ch/covid-19/innosuisse/49697.1%20IP-LS
A Swiss nasal spray could help against corona
9/12/21
At the very beginning of the corona pandemic, Swiss projects were also in the running for a vaccine. But without success. However, Swiss researchers are now using money from the National Fund to look again for corona vaccines, more or less next-generation vaccines.
https://www.srf.ch/audio/echo-der-zeit/ein-schweizer-nasenspray-koennte-gegen-corona-helfen?partId=12053097&ns_source=mobile&srg_sm_medium=tw
Courtesy of Volker Thiel ^
Global Fund Applauds Switzerland’s Leadership in The Global Fight Against COVID-19
https://reliefweb.int/report/world/global-fund-applauds-switzerland-s-leadership-global-fight-against-covid-19
Breakthrough Therapy Designation from the FDA came on the basis of results that are groundbreaking in the treatment of the life-threatening disease breast cancer. The results came from a clinical trial with IO Biotech's vaccines IO102 and IO103 in combination with existing treatment of 30 patients at Herlev Hospital.
The US approval from the FDA is a great advantage because it provides a faster and priority access to discussions with the FDA, and can thus result in a faster approval. IO Biotech expects that the remedy against fashion brand cancer may already be on the market by the end of 2023 or the beginning of 2024.
https://businessreview.dk/biotek/io-biotech-en-himmel-stormer-i-dansk-biotek/
https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/
I'm surprised Dr. Bottazzi would allow Basel King to muzzle her like that with a non disclosure agreement, etc.
Contradicts with her beliefs, being Editor-in-Chief of Springer's Current Tropical Medicine Reports and all.
Dr. Bottazzi knew right from the start.
"It is very likely that the coronavirus will become a virus that will be circulating every year" -2020-03-05
https://www.estrategiaynegocios.net/centroamericaymundo/1361648-330/mar%EDa-bottazzi-es-muy-probable-que-el-coronavirus-se-convierta-en-un
Keep up the good work and hope life is good SP1.
Nipah virus third generation virosome vaccine pr incoming.
Carmelina still screening his calls.
He needs to grow a pair.
No accountability.
Chris wears the pants in that house.
Feminine hypergamy in his forecast and will hit hard.
Hope he locked in those NLST gains.
Intranasal Droplets and Sprays Could Help Tackle SARS-CoV-2
Researchers from Freie Universität Berlin and the University of Bern have published the results of a groundbreaking study
from Aug 10, 2021
https://www.fu-berlin.de/en/presse/informationen/fup/2021/fup_21_155-studie-nasenspray-corona/index.html
SARS-CoV-2 vaccine candidates developed in this project offer three important advantages over most licensed vaccines and others still in development. First, vaccine candidates contain the entire viral buildup and are not limited to the viral spike protein. Second, vaccine administration is needle-free. Third, vaccines could be administered intranasally to induce immune responses at the site of infection.
Volker Thiel
Dear Dr. Staehelin and Mr. Kempers,
Who's going to carry the boats?
Corpus, Corpus, Corpus.
Does Mymetics have the delivery system being used by IO Biotech?
Will Mymetics benefit from Mai-Britt Zocca taking them public now that her "price is set towards the stock market?"
Interesting articles at the six and nine second mark(s):
https://www.facebook.com/EOYDanmark/videos/et-stort-tillykke-til-biotekselskabet-io-biotech-og-mai-britt-zocca-der-er-dette/926411171233439/
"We are working towards not just hitting the cancer cells but also the immune suppression in the tumor. Immune suppression is one of the biggest causes of the current treatments not working."
"The American health authorities in the USA have considered our treatment to be groundbreaking and promising that we must now embark on a major registration study in mother brand strength."
Mai-Britt Zocca, IO Biotech CEO, Denmark's EY Entrepreneur of the Year.
Don't let Staehelin throw you under the bus on this one Corpus.
regards,
Where you at Corpus?
Fiduciary duties of Disclosure, Loyalty and Care being met?
The SOX Act being followed?
"Be nice to the people on your way up the ladder because you'll meet them on your way down." - Wilson Mizner
Seagen and Astellas’ Padcev for Urothelial Cancer
https://www.biospace.com/article/fda-action-alert-amgen-seagen-astellas-enzon-sesen-biomarin-and-axsome/
Seagen, RemeGen Ink $2.6B License Agreement for Anti-HER2 Drug Disitamab Vedotin
Aug 13, 2021
https://www.precisiononcologynews.com/business-news/seagen-remegen-ink-26b-license-agreement-anti-her2-drug-disitamab-vedotin#.YR2e8mjYq3A
I know Moderna will be distributing their hiv vaccine before Kempers ever lands another CEO gig.
https://www.sciencealert.com/moderna-s-experimental-hiv-vaccine-could-begin-human-trials-as-soon-as-this-week
Doubt Monique Staehelin and Chris Kempers-Francke would put up with that.